Cl18.2
35 programs · 34 companies
Programs
35
Companies
34
Active Trials
22
Targeting Cl18.2
| Drug | Company | Phase | MOA | Indications |
|---|---|---|---|---|
| Mavutenlimab | Johnson & Johnson | Phase 3 | PNHSMA | |
| JNJ-2735 | Johnson & Johnson | Phase 2/3 | RCCGBM | |
| Ribosacituzumab | Roche | Approved | DLBCL | |
| Adagrazumab | Novartis | Phase 2/3 | Heart Failure | |
| Zorimavacamten | Bristol-Myers Squibb | Preclinical | Urothelial CaSMA | |
| Doxafotisoran | Daiichi Sankyo | Phase 1 | ALLGBM | |
| PRA-419 | Praxis Precision | Approved | ETHeart Failure | |
| CRB-3801 | Caribou Bio | Preclinical | CeliacBreast Ca | |
| Nidatapinarof | Ono Pharma | Phase 2 | Endometrial CaObesity | |
| Talavorutinib | Zai Lab | NDA/BLA | FL | |
| BHC-6524 | Bausch Health | Approved | Crohn'sNSCLC | |
| Zenoglumide | ProKidney | Preclinical | FTDCrohn's | |
| SWT-8357 | SpringWorks | Phase 1 | ET | |
| IMM-2816 | Immunomedics (Gilead) | Approved | LGSADPKD | |
| G1-8409 | G1 Therapeutics (Licella) | Phase 3 | DMDRCC | |
| Niramavacamten | Flatiron Health (Roche) | Preclinical | ALS | |
| Mirinaritide | Yuhan Corp | Phase 2/3 | ADHDMCC | |
| CHR-9224 | Chroma Med | Phase 2 | OCD | |
| Rilunaritide | NuCana | Approved | RettGastric Ca | |
| Semarasimod | Prothena | Phase 1/2 | PBC | |
| Fixafutibatinib | Soleno Ther | Phase 1 | T2DRCC | |
| RYT-3886 | Rhythm Pharma | Phase 2/3 | ADHDRB | |
| PLR-1516 | Pliant Ther | Phase 1 | MDDMDS | |
| Zenovorutinib | Avanir (Otsuka) | Preclinical | Endometrial Ca | |
| Ivosotorasib | Avrobio | Phase 2/3 | PBC | |
| NOI-4498 | Noile-Immune | Phase 1 | SLEPsA | |
| TCB-2352 | TC BioPharm | Approved | CSUPNH | |
| Sovarapivir | Lundbeck | Preclinical | EoETTR Amyloidosis | |
| BIO-1735 | Biogenesis Bago | Phase 2 | HNSCCADPKD | |
| Elraosocimab | Liomont | Phase 3 | PSPHCC | |
| NAT-IIT-794 | Natl Cancer Ctr Singapore | Approved | CML | |
| CAM-IIT-461 | CAMS Peking Union | Phase 1 | CML | |
| Fixatuximab | Bausch + Lomb | Phase 1/2 | AML | |
| DEC-8558 | Dechra Pharma (EQT) | Preclinical | ADPKD | |
| 115-4305 | Bridge Biotherapeutics | NDA/BLA | MCCSMA |